- Home
- TWFG vs PHAT Comparison
TWFG vs PHAT Comparison
Compare TWFG & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWFG
- PHAT
- Stock Information
- Founded
- TWFG 2001
- PHAT 2018
- Country
- TWFG United States
- PHAT United States
- Employees
- TWFG N/A
- PHAT N/A
- Industry
- TWFG
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- TWFG
- PHAT Health Care
- Exchange
- TWFG NYSE
- PHAT Nasdaq
- Market Cap
- TWFG 437.4M
- PHAT 423.4M
- IPO Year
- TWFG 2024
- PHAT 2019
- Fundamental
- Price
- TWFG $31.36
- PHAT $5.49
- Analyst Decision
- TWFG Buy
- PHAT Strong Buy
- Analyst Count
- TWFG 8
- PHAT 5
- Target Price
- TWFG $33.14
- PHAT $23.00
- AVG Volume (30 Days)
- TWFG 91.3K
- PHAT 1.6M
- Earning Date
- TWFG 05-15-2025
- PHAT 05-08-2025
- Dividend Yield
- TWFG N/A
- PHAT N/A
- EPS Growth
- TWFG N/A
- PHAT N/A
- EPS
- TWFG 0.19
- PHAT N/A
- Revenue
- TWFG $203,760,000.00
- PHAT $55,252,000.00
- Revenue This Year
- TWFG $22.49
- PHAT $202.16
- Revenue Next Year
- TWFG $18.64
- PHAT $113.86
- P/E Ratio
- TWFG $164.23
- PHAT N/A
- Revenue Growth
- TWFG 18.44
- PHAT 8001.47
- 52 Week Low
- TWFG $21.31
- PHAT $4.07
- 52 Week High
- TWFG $36.50
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- TWFG N/A
- PHAT 46.30
- Support Level
- TWFG N/A
- PHAT $4.76
- Resistance Level
- TWFG N/A
- PHAT $6.89
- Average True Range (ATR)
- TWFG 0.00
- PHAT 0.61
- MACD
- TWFG 0.00
- PHAT 0.00
- Stochastic Oscillator
- TWFG 0.00
- PHAT 50.35
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.